Untitled document
National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)
made under subsection 100(1) of the
National Health Act 1953
Compilation No. 76
Compilation date: 1 November 2017
Includes amendments up to: PB 88 of 2017
Registered: 1 November 2017
About this compilation
This compilation
This is a compilation of the National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010) that shows the text of the law as amended and in force on 1 November 2017 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register ( The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Editorial changes
For more information about any editorial changes made in this compilation, see the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
Contents
Part 1—Preliminary 1
Division 1—General 1
1............ Name of Special Arrangement....................................................................................... 1
4............ Definitions..................................................................................................................... 1
Division 2—HSD pharmaceutical benefits 7
5............ Pharmaceutical benefits covered by this Special Arrangement...................................... 7
6............ Application of Part VII of the Act................................................................................. 7
7............ Responsible person....................................................................................................... 7
8............ Authorised Prescriber.................................................................................................... 8
9............ Prescription circumstances............................................................................................ 8
9A......... HSD pharmaceutical benefits which may be supplied to public hospital admitted patients 8
Division 3—HSD Authority Required procedures 10
10.......... HSD Authority Required procedures.......................................................................... 10
Division 4—Maximum quantity and maximum number of repeats 11
14.......... Maximum quantity...................................................................................................... 11
15.......... Maximum number of repeats....................................................................................... 12
Division 5—Section 100 only 13
16.......... Section 100 only supply.............................................................................................. 13
Part 2—Supply of HSD pharmaceutical benefits 14
Division 1—General requirements for supply 14
17.......... Entitlement to HSD pharmaceutical benefits................................................................ 14
17A....... Modified application of paragraph 92A(1)(f) conditions of approval.......................... 14
18.......... Supply of HSD pharmaceutical benefits under this Special Arrangement................... 14
Division 2—Repeat prescriptions 16
19.......... Application of regulation 25........................................................................................ 16
20.......... No repeats for visitors................................................................................................. 16
Division 3—Prescribing HSD pharmaceutical benefits that have non‑CAR drugs 17
21.......... Methods of prescribing HSD pharmaceutical benefits that have non‑CAR drugs....... 17
22A....... Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have non‑CAR drugs........................................................................................................................... 17
Division 4—Prescribing HSD pharmaceutical benefits that have CAR drugs 18
23.......... Prescriptions for HSD pharmaceutical benefits that have CAR drugs......................... 18
23A....... Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have CAR drugs.................................................................................................................................... 18
24.......... HSD pharmaceutical benefits that have CAR drugs—quantity exceptions.................. 18
25.......... HSD pharmaceutical benefits that have CAR drugs—repeat exceptions..................... 23
26.......... Application of regulation 13 in relation to CAR drugs................................................ 28
Part 4—Claiming procedures and payment amounts 29
Division 2—Modified section 99AAA claims by approved public hospitals 29
Subdivision 1—General requirements 29
30.......... How claims to be made—modified section 99AAA claiming..................................... 29
31.......... Limit on number of prescriptions in one claim............................................................ 29
Subdivision 3—Payment of claims 29
35.......... Payments to suppliers that are approved hospital authorities for public hospitals........ 29
Division 3—Payments to suppliers of HSD pharmaceutical benefits that are approved hospital authorities for private hospitals or approved pharmacists or approved medical practitioners 30
36.......... Payments to certain suppliers of HSD pharmaceutical benefits................................... 30
Part 5—Dispensed price 31
Division 1—Dispensed price for supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital 31
37.......... The dispensed price—supply by public hospital......................................................... 31
38.......... Where quantity is less than a pack quantity................................................................. 31
Division 2—Dispensed price for supply of HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner 32
39.......... The dispensed price—supply by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner...................................................................................... 32
40.......... Mark‑up...................................................................................................................... 33
41.......... Where quantity is less than a pack quantity................................................................. 34
42.......... Dispensing fee............................................................................................................. 34
Division 3—Dispensed price—other matters 35
44.......... Rounding up of dispensed price.................................................................................. 35
Part 6—Patient contributions 36
46.......... Patient contributions in relation to approved hospital authorities................................. 36
47.......... Patient contributions for claims by approved pharmacists or approved medical practitioners 36
48.......... Additional patient contributions................................................................................... 36
Part 7—Miscellaneous 37
49.......... Compliance and audit arrangements............................................................................ 37
50.......... PBS Safety Net........................................................................................................... 37
51.......... Application of Act and Part VII instruments to approved suppliers and prescriptions etc 37
Part 8—Approval of certain hospital authorities 39
52.......... Approval of certain public hospital authorities............................................................ 39
Part 9—Transitional arrangements 40
53.......... Approvals of certain hospital authorities of public hospitals....................................... 40
54.......... Transitional arrangements for existing public hospital medication chart prescribing and paperless claiming 40
55.......... Transitional arrangements for existing non‑medication chart public hospital paperless claiming 40
56.......... Transitional arrangements for repeat prescriptions...................................................... 41
Schedule 1—Pharmaceutical benefits covered by this Special Arrangement and related information 42
Schedule 2—Responsible Person Codes 112
Schedule 3—Circumstances and Purposes Codes 114
Schedule 3 Part 1—General statement for drugs for the treatment of hepatitis C 456
Schedule 4—Patient contributions 462
Endnotes463
Endnote 1—About the endnotes 463
Endnote 2—Abbreviation key 464
Endnote 3—Legislation history 465
Endnote 4—Amendment history 469
Part 1—Preliminary
Division 1—General
1 Name of Special Arrangement
(1) This Special Arrangement is the National Health (Highly specialised drugs program) Special Arrangement 2010.
(2) This Special Arrangement may also be cited as PB 116 of 2010.
4 Definitions
In this Special Arrangement:
ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999.
accredited prescriber of medication for the treatment of hepatitis B means a medical practitioner approved by a State or Territory to prescribe medication for the treatment of hepatitis B for this Special Arrangement.
accredited prescriber of medication for the treatment of Hepatitis C means a medical practitioner approved by a State or Territory to prescribe medication for the treatment of Hepatitis C for this Special Arrangement.
accredited prescriber of medication for the treatment of HIV or AIDS means a medical practitioner approved by a State or Territory to prescribe medication for the treatment of HIV or AIDS for this Special Arrangement.
accredited prescriber of medication for the treatment of schizophrenia means a medical practitioner approved by a State or Territory to prescribe medication for the treatment of schizophrenia for this Special Arrangement.
Act means the National Health Act 1953.
affiliated specialist medical practitioner means a medical practitioner who:
(a) is affiliated with the hospital at or from which the patient is receiving treatment; and
(b) is either:
(i) a staff hospital specialist; or
(ii) a visiting or consulting specialist of the hospital.
approved hospital authority, for a hospital, means the hospital authority for the hospital that:
(a) is approved:
(i) by the Minister under section 94 of the Act; or
(ii) by the Chief Executive Medicare under section 52 of this Special Arrangement; or
(b) was approved under section 52 of the National Health (Highly specialised drugs program for public hospitals) Special Arrangements Instrument 2010 and the approval:
(i) is not suspended; or
(ii) has not been revoked.
Note: The Instrument mentioned in paragraph (b) is also known as PB 63 of 2010.
approved private hospital means a private hospital that has an approved hospital authority.
approved public hospital means a public hospital that has an approved hospital authority.
authorised prescriber, for an HSD pharmaceutical benefit, means a person who is a kind of person identified by a prescriber code mentioned in the column in Schedule 1 headed ‘Authorised Prescriber’ for the benefit.
benefit card means any of the following:
(a) a PBS Entitlement Card;
(b) a PBS Safety Net Concession Card;
(c) a Pensioner Concession Card;
(d) a Health Care Card (including Low Income Health Care Card and Foster Child Health Care Card);
(e) a Commonwealth Seniors Health Card;
(f) a Cleft Lip and Palate Card;
(g) a DVA Gold Card;
(h) a DVA White Card;
(i) a DVA Orange Card;
(j) War Widow/Widower Transport Card;
(k) a card or voucher approved by the Chief Executive Medicare for this paragraph.
CAR drug (Complex Authority Required drug) means any of the following highly specialised drugs:
a) abatacept
b) adalimumab
c) ambristenan
d) azacitidine
e) bosentan
f) eculizumab
g) eltrombopag
h) epoprostenol
i) etanercept
j) iloprost
k) infliximab
l) ivacaftor
m) lenalidomide
n) macitentan
o) mepolizumab
p) omalizumab
q) pasireotide
qa) pegvisomant
r) pomalidomide
s) riociguat
t) rituximab
u) romiplostim
v) sildenafil
w) tadalafil
x) tocilizumab
xa) ustekinumab
y) vedolizumab
circumstances code means the letter ‘C’ followed by a number.
Department means the Department administered by the Minister who administers the National Health Act 1953.
dispensed price:
(a) for the supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital—has the meaning given by section 37; and
(b) for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist—has the meaning given by section 39.
eligible medical practitioner, for the prescription of an HSD pharmaceutical benefit under this Special Arrangement to an eligible patient, means a person:
(a) who is an affiliated specialist medical practitioner; or
(b) who is, for the prescription of medication for the treatment of HIV or AIDS—an accredited prescriber of medication for the treatment of HIV or AIDS; or
(ba) who is, for the prescription of medication for the treatment of hepatitis B—an accredited prescriber of medication for the treatment of hepatitis B; or
(bb) who is, for the prescription of medication for the treatment of schizophrenia—an accredited prescriber of medication for the treatment of schizophrenia; or
(c) who is, for the prescription of medication for the treatment of hepatitis C:
(i) an accredited prescriber of medication for the treatment of hepatitis C; or
(ii) a medical practitioner, for Daclatasvir, Ledipasvir with sofosbuvir, Ribavirin, Sofosbuvir, Paritaprevir with ritonavir with ombitasvir and dasabuvir, Paritaprevir with ritonavir with ombitasvir and dasabuvir and ribavirin, and Grazoprevir with elbasvir; or
(d) who is, for the prescription of medication for maintenance therapy if it is impractical to obtain a prescription from the treating affiliated specialist medical practitioner and the treating staff hospital specialist has agreed to the prescription—a medical practitioner; or
(e) who is, for the prescription of medication for maintenance therapy—a medical practitioner whom the Commonwealth and the State or Territory Government has agreed may give such a prescription.
eligible patient means a person who
(a) is, or is to be treated as, an eligible person within the meaning of the Health Insurance Act 1973; and
(b) if receiving treatment at or from a public hospital, is receiving medical treatment by a medical practitioner as:
(i) a non‑admitted patient; or
(ii) a day admitted patient; or
(iii) a patient on discharge; or
(iv) an admitted patient who has been prescribed a HSD pharmaceutical benefit referred to in section 9A.
entitlement number, for a patient, means the number listed on the patient’s benefit card.
General Statement for drugs for the treatment of hepatitis C means the statement set out in Schedule 3 Part 1.
highly specialised drug means a listed drug mentioned in Schedule 1.
Note: Special Arrangements under section 100 of the Act apply to pharmaceutical benefits with drugs that have been declared by the Minister under subsection 85(2) of the Act. The drugs in Schedule 1 have all been so declared.
hospital authority means:
(a) for a public hospital—the governing body of the hospital; or
(b) for a private hospital—the proprietor of the hospital.
HSD pharmaceutical benefit means a pharmaceutical benefit mentioned in Schedule 1.
item code, for a drug that has a particular form, manner of administration and brand, means the code for the form, manner of administration and brand for the drug set out in the Department’s website.
Note: The website address is chart prescription has the meaning given in the Regulations, but does not include a medication chart prescription for a person receiving treatment in a residential care service.
medication for the treatment of hepatitis B means any of the following:
(a) adefovir
(b) entecavir
(c) interferon alfa‑2a
(d) interferon alfa‑2b
(e) lamivudine
(f) peginterferon alfa‑2a
(g) tenofovir
medication for the treatment of HIV or AIDS means any of the following:
(a) abacavir
(b) abacavir with lamivudine
(c) abacavir with lamivudine and zidovudine
(d) atazanavir
(da) atazanavir with cobicistat
(e) azithromycin
(f) darunavir
(g) darunavir with cobicistat
(h) didanosine
(i) dolutegravir
(j) dolutegravir with abacavir and lamivudine
(k) doxorubicin, pegylated liposomal
(l) efavirenz
(m) emtricitabine
(n) emtricitabine with rilpivirine with tenofovir alafenamide
(o) emtricitabine with tenofovir alafenamide
(p) enfuvirtide
(q) etravirine
(r) fosamprenavir
(s) foscarnet
(t) ganciclovir
(u) indinavir
(v) lamivudine
(w) lamivudine with zidovudine
(x) lopinavir with ritonavir
(y) maraviroc
(z) nevirapine
(za) raltegravir
(zb) rifabutin
(zc) rilpivirine
(zd) ritonavir
(ze) saquinavir
(zf) stavudine
(zg) tenofovir
(zh) tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat
(zi) tenofovir with emtricitabine
(zj) tenofovir with emtricitabine efavirenz
(zk) tenofovir with emtricitabine, elvitegravir and cobicistat
(zl) tenofovir with emtricitabine and rilpivirine
(zm) valganciclovir
(zn) tipranavir
(zo) zidovudine
medication for the treatment of schizophrenia means clozapine.
non‑CAR drug means a highly specialised drug that is not a complex authority required (CAR) drug.
other Special Arrangement means another Special Arrangement under section 100 of the Act.
prescriber code has the meaning given by paragraph 8(2)(b).
purposes code means the letter ‘P’ followed by a number.
residential care service has the meaning given by the Regulations.
Regulations means the National Health (Pharmaceutical Benefits) Regulations 1960.
streamlined authority code means the number mentioned in subsection 13(1).
under co‑payment data means information relating to a supply of a HSD pharmaceutical benefit by an approved pharmacist, approved medical practitioner or approved hospital authority for a hospital where a claim is not payable as the dispensed price for the supply of the HSD pharmaceutical benefit does not exceed the amount that the supplier was entitled to charge under subsection 46(2) or subsection 47(2) of this Special Arrangement.
Note: Terms used in this Special Arrangement have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:
· approved ex‑manufacturer price
· approved medical practitioner
· approved pharmacist
· claimed price
· hospital
· medical practitioner
· Chief Executive Medicare
· pack quantity
· pharmaceutical benefit
· pharmaceutical item
· private hospital
· proportional ex‑manufacturer price
· public hospital.
Division 2—HSD pharmaceutical benefits
5 Pharmaceutical benefits covered by this Special Arrangement
(1) This Special Arrangement applies to each HSD pharmaceutical benefit mentioned in Schedule 1.
(2) Each HSD pharmaceutical benefit to which this Special Arrangement applies is a brand of a listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
Note: Each listed drug mentioned in Schedule 1 is a highly specialised drug—see definition of highly specialised drug in section 4. Each listed drug has been declared by the Minister under subsection 85(2) of the Act. The form, manner of administration and brand mentioned in Schedule 1 have been determined by the Minister under subsections 85(3), (5) and (6) of the Act respectively.
Application of Part VII of the Act
(1) Each HSD pharmaceutical benefit supplied in accordance with this Special Arrangement is supplied under Part VII of the Act.
(2) A provision of Part VII of the Act, or of regulations or other instruments made for Part VII of the Act, applies subject to this Special Arrangement.
Note: See subsection 100(3) of the Act.
7 Responsible person
(1) If a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in paragraph (2)(a) is the responsible person for the brand of the pharmaceutical item.
(2) For subsection (1):
(a) the person is the person mentioned in Schedule 2 for the code, with the ABN, if any, mentioned in Schedule 2 for the person; and
(b) the pharmaceutical item is the listed drug mentioned in Schedule 1:
(i) in the form mentioned in Schedule 1 for the listed drug; and
(ii) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
Note 1: An HSD pharmaceutical benefit mentioned in Schedule 1 is a brand of a pharmaceutical item.
Note 2: A person identified by a code in the column headed ‘Responsible Person’ in Schedule 1 has been determined by the Minister, under section 84AF of the Act, to be the responsible person for the brand of the pharmaceutical item.
8 Authorised Prescriber
(1) Only an authorised prescriber may write a prescription for the supply of an HSD pharmaceutical benefit to an eligible patient.
(2) For this Special Arrangement:
(a) only an eligible medical practitioner is an authorised prescriber; and
(b) the prescriber code for the authorised prescriber is the letters ‘EMP’.
(3) A reference in this Special Arrangement to an eligible medical practitioner is a reference to an authorised prescriber.
(4) For subsection (1), the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(5) Subsection 88(1) of the Act does not apply to the supply of an HSD pharmaceutical benefit under this Special Arrangement.
9 Prescription circumstances
(1) If at least 1 circumstances code is mentioned in the column in Schedule 1 headed ‘Circumstances’ for an HSD pharmaceutical benefit, the circumstances mentioned in Schedule 3 for the code are the circumstances in which a prescription for the supply of the HSD pharmaceutical benefit may be written.
(2) For subsection (1), the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
9A HSD pharmaceutical benefits which may be supplied to public hospital admitted patients
The HSD pharmaceutical benefits which may be supplied to public hospital admitted patients under this Special Arrangement are referred to in the table below:
(a) if a drug is referred to in the table below and paragraphs (b), (c) and (d) do not apply – all HSD pharmaceutical benefits containing that drug;
(b) if a form of the drug is referred to in the table below and paragraphs (c) and (d) do not apply – all HSD pharmaceutical benefits containing that drug in that form;
(c) if a manner of administration of that form of the drug is referred to in the table below and paragraph (d) does not apply – all HSD pharmaceutical benefits containing that drug in that form with that manner of administration;
(d) if a brand of a drug in that form with that manner of administration is referred to in the table below – that brand of HSD pharmaceutical benefit containing that drug in that form with that manner of administration;
(e) if one or more circumstances and/or purposes code is identified in the table below – the HSD pharmaceutical benefit must be prescribed for one of those circumstances and/or purposes.
| Drug | Form | Manner of Administration | Brand | Circumstances Code | Purposes Code |
| eculizumab |
Note: A circumstances and/or purposes code mentioned in the above table is the same circumstances and/or purposes code referred to in section 9 (circumstances code) or section 14 or section 15 (purposes code).
Division 3—HSD Authority Required procedures
10HSD Authority Required procedures
(1) This section applies to an HSD pharmaceutical benefit if the circumstances mentioned in Schedule 3 for a circumstances code mentioned in Schedule 1 for the HSD pharmaceutical benefit includes:
(a) Compliance with Authority Required procedures;
(b) Compliance with Written Authority Required procedures;
(c) Compliance with Written or Telephone Authority Required procedures;
(d) Compliance with modified Authority Required procedures.
(1A) If the circumstances mentioned in Schedule 3 for a circumstances code mentioned in Schedule 1 for a HSD pharmaceutical benefit include ‘Compliance with Written or Telephone Authority Required procedures’ then treat as if the words used are ‘Compliance with Authority Required procedures’.
(2) The Authority Required procedures as provided for in sections 11 to 14 of the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 are to be followed.
(3) In addition to the requirements of subsection (2), where ‘Compliance with modified Authority Required procedures’ appears in the circumstances mentioned in Schedule 3 for the code, in addition to ‘Compliance with Written or Telephone Authority Required procedures’, any other requirement included in the circumstances is to be followed as part of the Authority Required procedures.
Division 4—Maximum quantity and maximum number of repeats
14 Maximum quantity
(1) The maximum quantity or number of units of the pharmaceutical item in an HSD pharmaceutical benefit that may, in 1 prescription for the supply of the HSD pharmaceutical benefit, be directed to be supplied by an eligible medical practitioner is the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ for the HSD pharmaceutical benefit.
(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for an HSD pharmaceutical benefit, the quantity or number of units mentioned in the column headed ‘Maximum Quantity’ is the maximum for the particular purposes mentioned in Schedule 3 for each code.
(3) If no purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’, the quantity or number of units mentioned in the column in Schedule 1 headed ‘Maximum Quantity’ is the maximum for all purposes, other than a purpose for which a different maximum is mentioned for the same HSD pharmaceutical benefit.
(4) For subsection (1), the pharmaceutical item is the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(5) For this section, the HSD pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(6) Subsection (1) applies, in relation to an HSD pharmaceutical benefit that has a CAR drug, subject to section 24.
Note 1: The maximum quantities and numbers of units mentioned in the column headed ‘Maximum quantity’ in Schedule 1 have been determined by the Minister under paragraph 85A(2)(a) of the Act.
Note 2: See also section 26.
(7) A determination made under paragraph 85A(2)(a) of the Act does not apply to an HSD pharmaceutical benefit supplied in accordance with this Special Arrangement in relation to the maximum quantity of the HSD pharmaceutical benefit that can be supplied under this Special Arrangement if the maximum quantity mentioned in the determination differs from the maximum quantity mentioned in this section.
15 Maximum number of repeats
(1) The maximum number of occasions an eligible medical practitioner may, in 1 prescription, direct that the supply of the pharmaceutical benefit be repeated is the number in the column in Schedule 1 headed ‘Number of Repeats’ for the pharmaceutical benefit.
(2) If at least 1 purposes code is mentioned in the column in Schedule 1 headed ‘Purposes’ for the pharmaceutical benefit, the number of repeats mentioned in the column in Schedule 1 headed ‘Number of Repeats’ is the maximum number for the particular purposes mentioned in Schedule 3 for each code.
(3) If no purposes code is mentioned in the column headed ‘Purposes’, the number of repeats mentioned in the column headed ‘Number of Repeats’ is the maximum number for all purposes, other than a purpose for which a different maximum is mentioned for the same pharmaceutical benefit.
(4) For this section, the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:
(a) in the form mentioned in Schedule 1 for the listed drug; and
(b) with the manner of administration mentioned in Schedule 1 for the form of the listed drug.
(5) Subsection (1) applies, in relation to an HSD pharmaceutical benefit that has a CAR drug, subject to section 25.
Note: See also section 26.
(6) A determination made under paragraph 85A(2)(b) of the Act does not apply to an HSD pharmaceutical benefit supplied in accordance with this Special Arrangement in relation to the maximum number of occasions an eligible medical practitioner may, in 1 prescription, direct, under this Special Arrangement, that the supply of the HSD pharmaceutical benefit be repeated if the maximum number mentioned in the determination differs from the maximum number mentioned in this section.
Division 5—Section 100 only
Section 100 only supply
(1) If the letter ‘D’ is mentioned in the column in Schedule 1 headed ‘Section 100 only’ for a listed drug, the listed drug may be supplied only in accordance with this Special Arrangement and any other Special Arrangement relating to the listed drug.
(2) An HSD pharmaceutical benefit that has a drug mentioned in subsection (1) is not available for general supply on the Pharmaceutical Benefits Scheme.
Note: The Minister has declared, under subsection 85(2A) of the Act, that the listed drug can only be supplied under a section 100 Special Arrangement.
(3) If the letters ‘PB’ are mentioned in the column in Schedule 1 headed ‘Section 100 only’ for an HSD pharmaceutical benefit, the HSD pharmaceutical benefit may be supplied only in accordance with this Special Arrangement and any other Special Arrangement relating to the pharmaceutical benefit.
(4) An HSD pharmaceutical benefit mentioned in subsection (3) is not available for general supply on the Pharmaceutical Benefits Scheme.
Note: The Minister has determined, under paragraph 85(8)(a) of the Act, that this HSD pharmaceutical benefit can only be supplied under a section 100 Special Arrangement.
(5) If the letter ‘C’ is mentioned in the column in Schedule 1 headed ‘Section 100 only’ for an HSD pharmaceutical benefit, the HSD pharmaceutical benefit may be supplied in the circumstances mentioned in Schedule 3 for the circumstances code in the column headed ‘Circumstances’ only in accordance with this Special Arrangement and any other Special Arrangement relating to the HSD pharmaceutical benefit.
(6) An HSD pharmaceutical benefit mentioned in subsection (5) is not available in the circumstances mentioned in subsection (5) for general supply on the Pharmaceutical Benefits Scheme.
Note: The Minister has determined, under paragraph 85(8)(b) of the Act, that 1 or more of the circumstances in which a prescription for the supply of the HSD pharmaceutical benefit may be written are circumstances in which the benefit can only be supplied under a section 100 Special Arrangement.
Part 2—Supply of HSD pharmaceutical benefits
Division 1—General requirements for supply
17 Entitlement to HSD pharmaceutical benefits
Subject to this Special Arrangement, an eligible patient is entitled to be supplied an HSD pharmaceutical benefit under this Special Arrangement without payment or other consideration, other than a charge made in accordance with Part 6.
17A Modified application of paragraph 92A(1)(f) conditions of approval
(1) Section 8 of the conditions of approval for approved pharmacists under paragraph 92A(1)(f) of the Act does not apply to the supply of a HSD pharmaceutical benefit, once prepared as a final product ready for infusion to a person, when the HSD pharmaceutical benefit has a physical, chemical or biological stability restricting its clinically effective shelf life to 8 hours or less.
(2) For the purposes of this section, shelf life means the period of time that a medicine can be stored and still be considered safe and effective for use.
18 Supply of HSD pharmaceutical benefits under this Special Arrangement
(1) Subject to subsection (2), this Special Arrangement only applies to the supply of an HSD pharmaceutical benefit:
(a) by an approved hospital authority for a public hospital to an eligible patient receiving treatment at or from an approved public hospital; or
(b) by an approved hospital authority for a private hospital to an eligible patient receiving treatment at or from an approved private hospital; or
(c) by an approved pharmacist to an eligible patient receiving treatment at or from a private hospital; or
(d) if the HSD pharmaceutical benefit has a CAR drug—by an approved pharmacist to an eligible patient receiving treatment at or from an approved public hospital or an approved private hospital.
(2) Where an eligible patient receives treatment in or at or outside of an approved public hospital or an approved private hospital, then a supplier listed in paragraph (a) may supply, to the eligible patient, HSD pharmaceutical benefits that are referred to in paragraph (b):
(a) The suppliers are:
i. an approved pharmacist; or
ii. an approved medical practitioner; or
iii. an approved hospital authority;
(b) The HSD pharmaceutical benefits are:
i. medication for the treatment of hepatitis B;
ii. medication for the treatment of HIV or AIDS, other than the pharmaceutical benefits containing the drugs azithromycin, doxorubicin ‑ pegylated liposomal and rifabutin; and
iii. medication for the treatment of schizophrenia when used in continuing therapy.
(3) This section does not require an approved hospital authority or an approved pharmacist to supply the HSD pharmaceutical benefit directly to a patient.
(4) The HSD pharmaceutical benefit may be supplied by the approved hospital authority or approved pharmacist through an agent.
(5) Section 94 of the Act applies in a modified manner to pharmaceutical benefits supplied by an approved hospital authority under this Special Arrangement.
Division 2—Repeat prescriptions
Application of regulation 25
Regulation 25 of the Regulations does not apply to the supply of HSD pharmaceutical benefits.
20 No repeats for visitors
An eligible medical practitioner must not write a repeat prescription for an HSD pharmaceutical benefit for a person who is a visitor to Australia even if the person is, in accordance with section 7 of the Health Insurance Act 1973, to be treated as an eligible person within the meaning of that Act.
Division 3—Prescribing HSD pharmaceutical benefits that have non‑CAR drugs
21 Methods of prescribing HSD pharmaceutical benefits that have non‑CAR drugs
An eligible medical practitioner may prescribe an HSD pharmaceutical benefit that has a non‑CAR drug under this Special Arrangement by:
(a) writing a prescription for the HSD pharmaceutical benefit in accordance with regulation 19 of the Regulations; or
(b) preparing a medication chart prescription for the HSD pharmaceutical benefit in accordance with regulation 19AA of the Regulations.
Note: An eligible medical practitioner may only prescribe more than the maximum quantity or more than the maximum number of repeats of an HSD pharmaceutical benefit that has a non‑CAR drug in accordance with Regulation 13.
22A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have non‑CAR drugs
(1) If an eligible medical practitioner prescribes a HSD pharmaceutical benefit referred to in section 9A for supply under Part VII of the Act, and that HSD pharmaceutical benefit has a non‑CAR drug, then either the:
(a) eligible medical practitioner; or
(b) approved hospital authority treating the eligible patient;
must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes.
(2) These records must be kept for 2 years after the date the prescription to which the records relate is written.
Division 4—Prescribing HSD pharmaceutical benefits that have CAR drugs
23 Prescriptions for HSD pharmaceutical benefits that have CAR drugs
An eligible medical practitioner may prescribe an HSD pharmaceutical benefit that has a CAR drug by writing a prescription for the HSD pharmaceutical benefit in accordance with regulation 19 of the Regulations.
23A Information to be kept for prescription of HSD pharmaceutical benefits referred to in section 9A that have CAR drugs
(1) If an eligible medical practitioner prescribes a HSD pharmaceutical benefit referred to in section 9A for supply under Part VII of the Act, and that HSD pharmaceutical benefit has a CAR drug, then either the:
(a) eligible medical practitioner; or
(b) approved hospital authority treating the eligible patient;
must keep a copy of any clinical records relating to the prescription, including such records required to demonstrate that the prescription was written in compliance with any relevant circumstances and/or purposes.
(2) These records must be kept for 2 years after the date the prescription to which the records relate is written.
24 HSD pharmaceutical benefits that have CAR drugs—quantity exceptions
(1) An eligible medical practitioner may write a prescription for an HSD pharmaceutical benefit that has a CAR drug mentioned in subsection (2) to be supplied to an eligible patient on any 1 occasion only in accordance with the limitation mentioned in subsection (2) for each HSD pharmaceutical benefit mentioned in subsection (2).
(2) The drugs and limitations are as follows:
(a) for HSD pharmaceutical benefits that have the drug ambrisentan, bosentan, epoprostenol, etanercept, iloprost, sildenafil or tadalafil—a quantity of units sufficient for up to 1 month of treatment with the drug;
(b) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with severe active rheumatoid arthritis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 3 milligrams per kilogram;
(c) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with active ankylosing spondylitis, severe active psoriatic arthritis or severe chronic plaque psoriasis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram;
(d) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of a patient with refractory Crohn disease or fistulating Crohn disease—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram;
(da) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of a patient with moderate to severe ulcerative colitis—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram.
(db) for HSD pharmaceutical benefits that have the drug infliximab, for the treatment of an adult with severe Crohn disease—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 5 milligrams per kilogram.
(e) for HSD pharmaceutical benefits that have the drug rituximab—a quantity of units sufficient to provide for a single dose;
(f) for HSD pharmaceutical benefits that have the drug abatacept—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose;
(g) for HSD pharmaceutical benefits that have the drug tocilizumab, for the treatment of adult patients with severe active rheumatoid arthritis—a quantity of units that are sufficient, based on the weight of the patient and taking into account whether any other strength injections will contribute part of the dose, to provide for the whole or part of a single dose of 8 mg per kg;
(h) for HSD pharmaceutical benefits that have the drug adalimumab—a quantity of units that are sufficient, based on the weight of the patient, to provide for 2 doses;
(i) for HSD pharmaceutical benefits that have the drug lenalidomide, for the treatment of a patient with multiple myeloma:
(i) with the form Capsule 5 mg—up to 84 tablets;
(ii) with the form Capsule 10 mg—up to 42 tablets;
(iii) with the form Capsule 15 mg—up to 21 tablets;
(iv) with the form Capsule 25 mg—up to 21 tablets;
(j) for HSD pharmaceutical benefits that have the drug lenalidomide, for the treatment of a patient with myelodysplastic syndrome:
(i) with the form Capsule 5 mg—up to 21 tablets;
(ii) with the form Capsule 10 mg—up to 21 tablets;
(k) for HSD pharmaceutical benefits that have the drug azacitidine with the form Powder for injection 100mg—up to 14 units.
(l) for HSD pharmaceutical benefits that have the drug romiplostim, for initial treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):
(i) at the time of the initial written authority application—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 1 microgram per kilogram;
(ii) during the initial period of dose titration—a quantity of units sufficient to provide for a single dose;
(iii) for a patient whose dose has been stable for a period of 4 weeks—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.
(m) for HSD pharmaceutical benefits that have the drug romiplostim, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Romiplostim prior to 1 April 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with Romiplostim was commenced:
(i) at the time of the initial written authority application—a quantity of units that are sufficient, based on the weight of the patient, to provide for a single dose of 1 microgram per kilogram;
(ii) during the initial period of dose titration—a quantity of units sufficient to provide for a single dose;
(iii) for a patient in the titration phase of treatment whose dose has been stable for a period of 4 weeks—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks;
(iv) for a patient whose dose had been stable for a period of at least 4 weeks at the time of the initial application for PBS‑subsidy—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment.
(n) for HSD pharmaceutical benefits that have the drug romiplostim, for the first period of continuing treatment or re‑initiation of interrupted PBS subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with Romiplostim during the initial period of PBS‑subsidised treatment—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks treatment.
(o) for HSD pharmaceutical benefits that have the drug romiplostim, for the second and subsequent periods of continuing treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who continues to display a sustained platelet response to treatment with Romiplostim—a quantity of units that are sufficient, based on the weight of the patient and the dose, for up to 4 weeks of treatment.
(p) for HSD pharmaceutical benefits that have the drug omalizumab, for initial treatment of uncontrolled severe allergic asthma—a quantity of units that are sufficient to provide for 28 weeks treatment;
(q) for HSD pharmaceutical benefits that have the drug omalizumab, for initial PBS‑subsidised treatment of uncontrolled severe allergic asthma in a patient who has previously received non‑PBS‑subsidised therapy with omalizumab (grandfather patients)—a quantity of units that are sufficient to provide for 24 weeks treatment;
(r) for HSD pharmaceutical benefits that have the drug omalizumab, for continuing treatment—a quantity of units that are sufficient to provide for 24 weeks treatment.
(ra) for HSD pharmaceutical benefits that have the drug omalizumab, for the treatment of severe chronic spontaneous urticaria:
(i) for initial treatment—a quantity of units that are sufficient to provide for 12 weeks treatment;
(ii) for initial PBS-subsidised treatment in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfathered patients)—a quantity of units that are sufficient to provide for 24 weeks treatment;
(iii) for continuing treatment—a quantity of units that are sufficient to provide for 24 weeks treatment.
(s) for HSD pharmaceutical benefits that have the drug eltrombopag, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):
(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;
(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;
—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.
(t) for HSD pharmaceutical benefits that have the drug eltrombopag, for initial PBS‑subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Eltrombopag prior to 1 November 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with Eltrombopag was commenced):
(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;
(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;
—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.
(u) for HSD pharmaceutical benefits that have the drug eltrombopag, for the first period of continuing treatment or re‑initiation of interrupted PBS subsidised treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who has displayed a sustained platelet response to treatment with Eltrombopag during the initial period of PBS‑subsidised treatment:
(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;
(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;
—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.
(v) for HSD pharmaceutical benefits that have the drug eltrombopag, for the second and subsequent periods of continuing treatment as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) of severe thrombocytopenia in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who continues to display a sustained platelet response to treatment with Eltrombopag:
(i) with the form Tablet 25 mg (as olamine)—up to 28 tablets;
(ii) with the form Tablet 50 mg (as olamine)—up to 28 tablets;
—a quantity of units that are sufficient for up to 4 weeks of treatment, as long as the total period of treatment that has been authorised does not exceed 24 weeks.
(w) for HSD pharmaceutical benefits that have the drug tocilizumab, for the treatment of patients with severe active systemic juvenile idiopathic arthritis—a quantity of units sufficient for up to 1 month of treatment with the drug.
(x) for HSD pharmaceutical benefits that have the drug riociguat, for the treatment of Chronic thromboembolic pulmonary hypertension (CTEPH):
(i) for Grandfathered patients—the maximum quantity authorised will be limited to provide sufficient supply for 1 month.
(ii) for Initial treatment—prescriptions for dose titration must provide sufficient quantity for dose titrations by 0.5 mg increments at 2‑week intervals to achieve up to a maximum of 2.5 mg three times daily. Approvals for subsequent authority prescriptions will be limited to 1 month of treatment.
(iii) for Continuing treatment—the maximum quantity per prescription will be limited to provide sufficient supply for 1 month of treatment.
(y) for HSD pharmaceutical benefits that have the drug riociguat, for balance of supply for patient who has received insufficient therapy with this agent:
(i) for Grandfathering—maximum of 24 weeks of treatment.
(ii) for Initial treatment—maximum of 20 weeks of treatment.
(iii) for Continuing treatment—maximum of 24 weeks of treatment—the treatment must provide no more than the balance up to 20 or 24 weeks of treatment available under the above respective restriction.
(z) for HSD pharmaceutical benefits that have the drug riociguat, for the treatment of Pulmonary arterial hypertension (PAH):
(i) for Initial 1(new patients), Initial 2 (new patients) and Initial 3 (change or re‑commencement of therapy for all patients) – prescriptions for dose titration will provide sufficient quantity for dose titrations by 0.5 mg increments at 2‑week intervals to achieve up to a maximum of 2.5 mg three times daily. Approvals for subsequent authority prescriptions will be limited to 1 month of treatment.
(ii) for Initial 4 (Grandfathered patients), Initial 5 (Grandfathered patients), First Continuing treatment and Subsequent Continuing treatment – the maximum quantity authorised will be limited to provide sufficient supply for 1 month of treatment.
(iii) for Initial 1 (new patients) or Initial 2 (new patients) or Initial 3 (change or re‑commencement of therapy for all patients) or First Continuing treatment – Balance of supply – the treatment must provide no more than the balance of up to six months treatment.
(za) for HSD pharmaceutical benefits that have the drug pasireotide, for the treatment of acromegaly:
(i) with the form Injection (modified release) 20 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes;
(ii) with the form Injection (modified release) 40 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes;
(iii) with the form Injection (modified release) 60 mg (as embonate), vial and diluent syringe—up to 2 vials and diluent syringes.
(zb) for HSD pharmaceutical benefits that have the drug pegvisomant, for the treatment of acromegaly:
(i) for initial treatment, for the 80 mg loading dose—4 x injection set containing powder for injection 20 mg, 1 and diluent, 1;
(ii) for initial treatment (subsequent doses)—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30;
(iii) for initial PBS-subsidised treatment in a patient who has previously received non-PBS-subsidised therapy with pegvisomant—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30;
(iv) for continuing treatment—1 x injection set containing powder for injection 10 mg, 15 mg or 20 mg, 30 and diluent, 30.
(zc) for HSD pharmaceutical benefits that have the drug ustekinumab, for the treatment of severe Crohn disease:
(i) for initial treatment, for a weight-based loading dose—up to 4 vials of Solution for I.V. infusion 130 mg in 26 mL;
(ii) for a change or re-commencement of treatment, for a weight-based loading dose—up to 4 vials of Solution for I.V. infusion 130 mg in 26 mL.
(zd) for HSD pharmaceutical benefits that have the drug vedolizumab, for the treatment of moderate to severe ulcerative colitis—the appropriate number of vials to provide for a single infusion of 300 mg per dose.
(ze) for HSD pharmaceutical benefits that have the drug vedolizumab, for the treatment of severe Crohn disease— the appropriate number of vials to provide for a single infusion of 300 mg.
25 HSD pharmaceutical benefits that have CAR drugs—repeat exceptions
(1) An eligible medical practitioner may authorise the repeat supply of an HSD pharmaceutical benefit that has a CAR drug mentioned in subsection (2) only in accordance with the limitations mentioned in subsection (2) for the drug.
(2) The drugs and limitations are as follows:
(a) for bosentan:
(i) if the prescription is for the balance of a 6 month course of initial treatment for a patient who has been issued with an authority prescription for the first month of the 6 month course—up to 4 repeat supplies; or
(ii) if the prescription is for continuing treatment of a patient who has achieved a response to his or her most recent course of PBS‑subsidised treatment—up to 5 repeat supplies;
(b) for etanercept:
(i) for the initial treatment of severe polyarticular course juvenile chronic arthritis—up to 3 repeat supplies; or
(ii) for the continuing treatment of severe polyarticular course juvenile chronic arthritis—up to 5 repeat supplies;
(c) for infliximab, for the treatment of an adult with severe active rheumatoid arthritis:
(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or
(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;
(d) for infliximab, for the treatment of an adult with severe active psoriatic arthritis:
(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or
(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;
(e) for infliximab, for the treatment of an adult with active ankylosing spondylitis—up to 3 repeat supplies;
(f) for infliximab, for the treatment of a patient with refractory Crohn disease or fistulating Crohn disease—up to 2 repeat supplies;
(g) for infliximab, for the treatment of an adult with severe chronic plaque psoriasis:
(i) if the circumstances permit a course of up to a maximum of 22 weeks of treatment to be authorised—up to 3 repeat supplies; or
(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 2 repeat supplies;
(ga) for infliximab, for the treatment of a patient with moderate to severe ulcerative colitis:
(i) for initial treatment (new patient or re-commencement of treatment after more than 5 years break in therapy)—up to 2 repeat supplies;
(ii) for a change or re-commencement of treatment after a break in therapy—up to 2 repeat supplies;
(iii) forcontinuing treatment—up to 2 repeat supplies.
(gb) for infliximab, for the treatment of an adult with severe Crohn disease:
(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;
(ii) for a change or re-commencement of treatment (initial 2)—up to 2 repeat supplies;
(iii) for continuing treatment—up to 2 repeat supplies.
(h) for abatacept, for the treatment of an adult with severe active rheumatoid arthritis:
(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 4 repeat supplies; or
(ii) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;
(i) for rituximab—1 repeat supply;
(j) for ambrisentan:
(i) for the initial PBS‑subsidised treatment of a patient who was receiving non‑PBS‑subsidised treatment with ambrisentan for less than 6 months before 1 December 2009—sufficient repeat supplies to allow the patient to complete a period of combined PBS‑subsidised and non‑PBS‑subsidised therapy of up to 6 months duration in total; or
(ii) if subparagraph (i) does not apply—up to 5 repeat supplies;
(k) for lenalidomide, for the treatment of a patient with multiple myeloma—up to 2 repeat supplies;
(l) for lenalidomide, for the treatment of a patient with myelodysplastic syndrome—up to 3 repeat supplies;
(m) for epoprostenol, iloprost, sildenafil, or tadalafil—up to 5 repeat supplies;
(n) for tocilizumab, for the treatment of adults with severe active rheumatoid arthritis:
(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;
(ii) If the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;
(o) for adalimumab for the treatment of a patient with juvenile idiopathic arthritis:
(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;
(ii) if the circumstances permit a course of up to a maximum of 24 weeks treatment to be authorised—up to 5 repeat supplies;
(p) for azacitidine:
(i) for initial treatment—up to 2 repeat supplies;
(ii) for continuing treatment—up to 5 repeat supplies.
(q) for romiplostim for initial treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):
(i) at the time of the initial written authority application—1 repeat supply;
(ii) during the initial period of dose titration—1 repeat supply;
(iii) for a patient whose dose has been stable for a period of 4 weeks—up to 4 repeat supplies.
(r) for romiplostim for initial PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with Romiplostim prior to 1 April 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with romplostin was commenced:
(i) at the time of the initial written authority application—1 repeat supply;
(ii) during the initial period of dose titration—1 repeat supply;
(iii) for a patient in the titration phase of treatment whose dose has been stable for a period of 4 weeks—up to 4 repeat supplies;
(iv) for a patient whose dose had been stable for a period of at least 4 weeks at the time of the initial application for PBS‑subsidy—up to 5 repeat supplies.
(s) for romiplostim for the first period of continuing treatment or re‑initiation of interrupted PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who has displayed a sustained platelet response to treatment with Romiplostim during the initial period of PBS‑subsidised treatment:
(i) at the time of the initial written authority application—up to 5 repeat supplies;
(ii) where less than 5 repeat supplies are requested in the initial written authority application—sufficient repeat supplies to complete a maximum of 24 weeks treatment.
(t) for romiplostim for the second and subsequent periods of continuing treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who continues to display a sustained platelet response to treatment with Romiplostim—up to 5 repeat supplies.
(u) for omalizumab—where fewer than the required number of repeats to complete 24 weeks of treatment are requested at the time of the authority application—sufficient repeat supplies to complete 24 weeks of treatment.
(v) for omalizumab—where at least 24 weeks treatment was requested at the time of the application—0 repeat supplies.
(va) for omalizumab, for the treatment of severe chronic spontaneous urticaria:
(i) for initial treatment—where the patient has received a quantity of units that are sufficient to provide for 12 weeks treatment—0 repeat supplies;
(ii) for initial PBS-subsidised treatment in a patient who has previously received non-PBS-subsidised therapy with omalizumab (grandfathered patients)—where the patient has received a quantity of units that are sufficient to provide for 24 weeks treatment—0 repeat supplies;
(iii) for continuing treatment—where the patient has received a quantity of units that are sufficient to provide for 24 weeks treatment—0repeat supplies;
(w) for eltrombopag for initial treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP):
(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.
(x) for eltrombopag for initial PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) who was receiving treatment with eltrombopag prior to 1 November 2011 and in whom the criteria for initial treatment in the circumstances can be demonstrated to have been met at the time his or her treatment with eltrombopag was commenced:
(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.
(y) for eltrombopag for the first period of continuing treatment or re‑initiation of interrupted PBS‑subsidised treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who has displayed a sustained platelet response to treatment with eltrombopag during the initial period of PBS‑subsidised treatment:
(i) if the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies;
(ii) where less than 5 repeat supplies are requested in the initial written authority application—sufficient repeat supplies to complete a maximum of 24 weeks treatment.
(z) for eltrombopag for the second and subsequent periods of continuing treatment of severe thrombocytopenia as the sole PBS‑subsidised thrombopoetin receptor agonist (TRA) in an adult with severe chronic immune (idiopathic) thrombocytopenic purpure (ITP) who continues to display a sustained platelet response to treatment with eltrombopag—up to 5 repeat supplies.
(za) for tocilizumab, for the treatment of patients with severe active systemic juvenile idiopathic arthritis:
(i) if the circumstances permit a course of up to a maximum of 16 weeks of treatment to be authorised—up to 3 repeat supplies;
(ii) If the circumstances permit a course of up to a maximum of 24 weeks of treatment to be authorised—up to 5 repeat supplies.
(zb) for riociguat, for the treatment of Chronic thromboembolic pulmonary hypertension (CTEPH):
(i) for grandfathering—up to 5 repeat supplies.
(ii) for initial treatment—up to 3 repeat supplies.
(iii) for continuing treatment—up to 5 repeat supplies.
(zc) for riociguat, for the treatment of Pulmonary arterial hypertension (PAH):
(i) for Initial 1 (new patients), Initial 2 (new patients) and Initial 3 (change or re‑commencement of therapy for all patients) – up to 4 repeat supplies.
(ii) for Initial 4 (Grandfathered patients), Initial 5 (Grandfathered patients), First Continuing treatment and Subsequent Continuing treatment – up to 5 repeat supplies.
(zd) for pasireotide—up to 5 repeat supplies.
(ze) for pegvisomant:
(i) for initial treatment, for the 80 mg loading dose—0 repeat supplies;
(ii) for intitial treatment (subsequent doses)—up to 5 repeat supplies;
(iii) for initial PBS-subsidised treatment in a patient who has previously received non-PBS-subsidised therapy with pegvisomant—up to 5 repeat supplies;
(iv) for continuing treatment—up to 5 repeat supplies.
(zf) for ustekinumab:
(i) for initial treatment, for a weight-based loading dose—0 repeat supplies;
(ii) for a change or re-commencement of treatment, for a weight-based loading dose——0 repeat supplies.
(zg) for vedolizumab, for the treatment of severe Crohn disease:
(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;
(ii) for a change or re-commencement of treatment (initial 2)—up to 2 repeat supplies;
(iii) for initial PBS-subsidised treatment (grandfather)—up to 2 repeat supplies;
(iv) for continuing treatment—up to 2 repeat supplies.
(zh) for vedolizumab, for the treatment of moderate to severe ulcerative colitis:
(i) for initial treatment (new patient – initial 1)—up to 2 repeat supplies;
(ii) for a change or re-commencement of treatment after a break in therapy (initial 2)—up to 2 repeat supplies;
(iii) for initial PBS-subsidised treatment (grandfather patient)—up to 2 repeat supplies;
(iv) for continuing treatment—up to 2 repeat supplies.
(3) In this section, circumstances means circumstances mentioned in Schedule 3 for the circumstances code mentioned in the column in Schedule 1 headed ‘Circumstances’ for the HSD pharmaceutical benefit that has the drug.
Application of regulation 13 in relation to CAR drugs
Regulation 13 of the Regulations does not apply in relation to a prescription for an HSD pharmaceutical benefit that has a CAR drug supplied under this Special Arrangement.
Part 4—Claiming procedures and payment amounts
Division 2—Modified section 99AAA claims by approved public hospitals
Subdivision 1—General requirements
How claims to be made—modified section 99AAA claiming
An approved hospital authority for a public hospital may make a claim for payment for the supply of an HSD pharmaceutical benefit in accordance with the rules made by the Minister under subsection 99AAA(8) of the Act, as modified by this Division.
Note 1: An approved hospital authority for a public hospital that may make a modified section 99AAA claim may choose instead to make the claim in accordance with the rules made by the Minister under subsection 99AAA(8) of the Act.
31 Limit on number of prescriptions in one claim
The claim for payment must not contain more than 3 500 prescriptions.
Subdivision 3—Payment of claims
35 Payments to suppliers that are approved hospital authorities for public hospitals
(1) An approved hospital authority for a public hospital is entitled to be paid the amount, if any, by which the dispensed price for the supply of the HSD pharmaceutical benefit exceeds the amount that the approved hospital authority was entitled to charge under subsection 46(2).
(2) The dispensed price is to be worked out in accordance with Division 1 of Part 5.
(3) No mark ups may be added to the cost of an HSD pharmaceutical benefit for which payment is claimed under this Division.
Division 3—Payments to suppliers of HSD pharmaceutical benefits that are approved hospital authorities for private hospitals or approved pharmacists or approved medical practitioners
36 Payments to certain suppliers of HSD pharmaceutical benefits
(1) An approved hospital authority for a private hospital is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for its supply of the HSD pharmaceutical benefit is greater than the amount that the approved hospital authority was entitled to charge under subsection 46(2).
(2) An approved pharmacist or an approved medical practitioner is entitled to be paid by the Commonwealth the amount, if any, by which the dispensed price for the supply of an HSD pharmaceutical benefit is greater than the amount that the approved pharmacist or approved medical practitioner was entitled to charge under subsection 47(2).
(3) The dispensed price for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or by an approved medical practitioner is to be worked out under Division 2 of Part 5.
Note: An approved hospital authority for a private hospital or an approved pharmacist may make claims for payment in accordance with rules made by the Minister under subsection 99AAA(8) of the Act—see section 99AAA(2) of the Act.
Part 5—Dispensed price
Division 1—Dispensed price for supply of an HSD pharmaceutical benefit by a hospital authority for a public hospital
37 The dispensed price—supply by public hospital
Subject to section 43, the dispensed price for the supply of an HSD pharmaceutical benefit, by a hospital authority for a public hospital, is as follows:
(a) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity of the benefit—the sum of the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity;
(b) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit—the amount calculated in accordance with section 38;
(c) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity of the benefit—the sum of:
(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity; and
(ii) the amount calculated in accordance with section 38 for the remainder of the quantity supplied that is less than a pack quantity.
38 Where quantity is less than a pack quantity
If the quantity of an HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a broken quantity), the amount mentioned in paragraph 37(b) and subparagraph 37(c)(ii) is to be calculated by:
(a) dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and
(b) applying that percentage to the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity.
Division 2—Dispensed price for supply of HSD pharmaceutical benefit by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner
39 The dispensed price—supply by an approved hospital authority for a private hospital or by an approved pharmacist or approved medical practitioner
(1) The dispensed price for the supply of an HSD pharmaceutical benefit by an approved hospital authority for a private hospital, or by an approved pharmacist, or by an approved medical practitioner, is as follows:
(a) if the quantity of the HSD pharmaceutical benefit that is ordered and supplied is equal to a multiple of a pack quantity, the sum of:
(i) the approved ex‑manufacturer price or the proportional ex‑manufacturer price for each pack quantity, plus the mark‑up mentioned in section 40, taken to the nearest cent, with one half cent being rounded up to 1 cent; and
(ii) either:
(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or
(B) if the HSD pharmaceutical benefit has a drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee mentioned in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or
(b) if a quantity of the HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity, the sum of:
(i) the amount calculated in accordance with section 41; and
(ii) either:
(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or
(B) if the HSD pharmaceutical benefit has a drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee mentioned in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or
(c) if a quantity of the HSD pharmaceutical benefit that is ordered and supplied is more than a multiple of a pack quantity, the sum of:
(i) for each pack quantity, the approved ex‑manufacturer price or the proportional ex‑manufacturer price for the pack quantity, plus the mark‑up mentioned in section 40, taken to the nearest cent, with one half cent being counted as 1 cent; and
(ii) the amount calculated in accordance with section 41 for the remainder of the quantity supplied that is less than a pack quantity; and
(iii) either:
(A) a dispensing fee equal to the dispensing fee for the supply of a ready prepared pharmaceutical benefit, mentioned in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit; or
(B) if the HSD pharmaceutical benefit has the drug mentioned in subsection (2) in the form mentioned in that subsection for the drug—the extemporaneously‑prepared dispensing fee set out in the the determination made under paragraph 98B(1)(a) of the Act, as in force at the time of the supply of the HSD pharmaceutical benefit.
(2) For sub‑subparagraphs (1)(a)(ii)(B), (1)(b)(ii)(B) and (1)(c)(iii)(B), the drugs and the forms for the drugs are as follows:
(a) mycophenolic acid as a powder for oral suspension containing mycophenolate mofetil 1g per 5 mL, 165mL;
(c) valganciclovir as a powder for oral solution 50mg (as hydrocholoride) per mL, 100 mL.
40 Mark‑up
For subparagraphs 39(1)(a)(i) and 39(1)(c)(i) and paragraph 41(a), the mark‑up for a pack quantity of a ready‑prepared pharmaceutical benefit is:
(a) if the pack quantity for which a mark‑up is to be calculated under this section is equal to a maximum quantity of the HSD pharmaceutical benefit, the mark‑up is the amount mentioned in the table below for the approved ex‑manufacturer price (AEMP) or proportional ex‑manufacturer price (PEMP) for that quantity.
| Item | AEMP or PEMP for Maximum Quantity | Mark‑up for Maximum Quantity |
| 1 | < $40 | 10% of AEMP or PEMP |
| 2 | ≥ $40, ≤ $100 | $4.00 |
| 3 | > $100, ≤ $1,000 | 4% of AEMP or PEMP |
| 4 | > $1,000 | $40.00 |
(b) if the pack quantity for which a mark‑up is to be calculated under this section is not equal to a maximum quantity of the HSD pharmaceutical benefit, the mark‑up is worked out as follows:
(i) if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a monetary amount—the mark‑up for the pack quantity is that monetary amount reduced proportionately for the relative quantities; and
(ii) if the mark‑up that would apply to the maximum quantity is shown in the table in paragraph (a) as a percentage of AEMP or PEMP—the mark‑up for the pack quantity is that percentage of the AEMP or PEMP for the pack quantity.
41 Where quantity is less than a pack quantity
If the quantity of an HSD pharmaceutical benefit that is ordered and supplied is less than a pack quantity of the benefit (a broken quantity), the amount mentioned in subparagraph 39(b)(i) and 39(c)(ii) is to be calculated by:
(a) adding the mark‑up mentioned in section 40 to the approved ex‑manufacturer price or the proportional ex‑manufacturer price for the pack quantity, taking the result to the nearest cent, with one half cent being counted as 1 cent; and
(b) dividing the quantity or number of units in the broken quantity by the pack quantity, expressed as a percentage to 2 decimal places; and
(c) applying the percentage worked out under subparagraph (b) to the amount worked out under subparagraph (a).
42 Dispensing fee
If an eligible medical practitioner, instead of directing a repeated supply of an HSD pharmaceutical benefit, directs the supply on one occasion of a quantity or number of units of the drug, not exceeding the total quantity or number of units that could be prescribed if the eligible medical practitioner directed a repeated supply, the dispensed price for the supply of the HSD pharmaceutical benefit will include only one dispensing fee.
Division 3—Dispensed price—other matters
44 Rounding up of dispensed price
The dispensed price for the supply of an HSD pharmaceutical benefit will in each case be taken to the nearest cent, one half cent being counted as one cent.
Part 6—Patient contributions
46 Patient contributions in relation to approved hospital authorities
(1) This section applies to an approved hospital authority for a public hospital or a private hospital that supplies an HSD pharmaceutical benefit.
| C7158 | Where the patient is receiving treatment at/from a private or public hospital Severe Crohn disease Change or Re-commencement of treatment (initial 2) Patient must have a documented history of severe Crohn disease; AND Patient must have received prior PBS-subsidised treatment with a biological disease modifying drug for this condition in this treatment cycle; AND Patient must not have failed PBS-subsidised therapy with this drug for this condition in the current treatment cycle; AND Patient must be appropriately assessed for the risk of developing progressive multifocal leukoencephalopathy whilst on this treatment. Patient must be aged 18 years or older. Must be treated by a gastroenterologist (code 87); OR Must be treated by a consultant physician [internal medicine specialising in gastroenterology (code 81)]; OR Must be treated by a consultant physician [general medicine specialising in gastroenterology (code 82)]. Applications for authorisation must be made in writing and must include: (a) a completed authority prescription form; and (b) a completed Crohn Disease PBS Authority Application - Supporting Information Form, which includes the following: (i) the completed Crohn Disease Activity Index (CDAI) Score calculation sheet including the date of the assessment of the patient's condition, if relevant; or (ii) the reports and dates of the pathology or diagnostic imaging test(s) used to assess response to therapy for patients with short gut syndrome, extensive small intestine disease or an ostomy, if relevant; and (iii) the date of clinical assessment; and (iv) the details of prior biological disease modifying drug treatment including the details of date and duration of treatment. To demonstrate a response to treatment the application must be accompanied by the results of the most recent course of biological disease modifying drug (bDMD) therapy within the timeframes specified in the relevant restriction. Where the most recent course of PBS-subsidised bDMD treatment was approved under an initial treatment restriction, the patient must have been assessed for response to that course following a minimum of 12 weeks of therapy for adalimumab and up to 12 weeks after the first dose (6 weeks following the third dose) for infliximab and vedolizumab and this assessment must be submitted to the Department of Human Services no later than 4 weeks from the date that course was ceased. If the response assessment to the previous course of bDMD treatment is not submitted as detailed above, the patient will be deemed to have failed therapy with that particular course of bDMD. A maximum quantity and number of repeats to provide for an initial course of this drug consisting of one vial of 300 mg per dose, with one dose to be administered at weeks 0, 2 and 6, will be authorised. If fewer than the maximum stated repeats in the relevant treatment phase are requested at the time of the application, authority approvals for sufficient repeats to complete the balance of the stated repeats in the relevant treatment phase may be requested by telephone by contacting the Department of Human Services and applying through the Balance of Supply restriction. Under no circumstances will telephone approvals be granted for treatment that would otherwise extend the relevant treatment phase. The assessment of the patient's response to this initial course of treatment must be made up to 12 weeks after the first dose (6 weeks following the third dose) so that there is adequate time for a response to be demonstrated. This assessment, which will be used to determine eligibility for continuing treatment, must be submitted to the Department of Human Services no later than 1 month from the date of completion of this initial course of treatment. Where a response assessment is not undertaken and submitted to the Department of Human Services within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug. | Compliance with Written Authority Required procedures | ||
| Zidovudine | C4454 | HIV infection Continuing treatment Patient must have previously received PBS‑subsidised therapy for HIV infection; AND The treatment must be in combination with other antiretroviral agents | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 4454 | |
| C4512 | HIV infection Initial treatment Patient must be antiretroviral treatment naïve; AND The treatment must be in combination with other antiretroviral agents | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 4512 | ||
| Zoledronic acid | C5605 | P5605 | Where the patient is receiving treatment at/from a public hospital Bone metastases The condition must be due to breast cancer. | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 5605 |
| C5606 | P5606 | Where the patient is receiving treatment at/from a private hospital Bone metastases The condition must be due to castration‑resistant prostate cancer. | Compliance with Written or Telephone Authority Required procedures | |
| C5676 | P5676 | Where the patient is receiving treatment at/from a private hospital Multiple myeloma | Compliance with Written or Telephone Authority Required procedures | |
| C5677 | P5677 | Where the patient is receiving treatment at/from a private hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti‑neoplastic therapy. | Compliance with Written or Telephone Authority Required procedures | |
| C5703 | P5703 | Where the patient is receiving treatment at/from a public hospital Bone metastases The condition must be due to castration‑resistant prostate cancer. | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 5703 | |
| C5704 | P5704 | Where the patient is receiving treatment at/from a public hospital Hypercalcaemia of malignancy Patient must have a malignancy refractory to anti‑neoplastic therapy. | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 5704 | |
| C5735 | P5735 | Where the patient is receiving treatment at/from a public hospital Multiple myeloma | Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 5735 | |
| C5736 | P5736 | Where the patient is receiving treatment at/from a private hospital Bone metastases The condition must be due to breast cancer. | Compliance with Written or Telephone Authority Required procedures |
Schedule 3 Part 1—General statement for drugs for the treatment of hepatitis C
1 Criteria for eligibility for drugs for the treatment of chronic hepatitis C
The criteria for patient eligibility for drugs for the treatment of chronic hepatitis C are that:
(1) the patient is 18 years or older; and
(2) the patient has been assessed in accordance with paragraph 2 of this Part; and
(3) the patient is:
a. treated by a medical practitioner who is experienced in the treatment of patients with chronic hepatitis C infection; or
b. treated by a medical practitioner in consultation with a gastroenterologist, a hepatologist or an infectious diseases physician who is experienced in the treatment of patients with chronic hepatitis C infection
2 Assessment of patient
For the purpose of subparagraph 1(2) of this Part, the patient has been assessed if the treating medical practitioner has:
(1) documented the following information in the patient’s medical records:
a. evidence of chronic hepatitis C infection; and
b. evidence of the patient’s hepatitis C virus genotype; and
(2) chosen a regimen in accordance with paragraph 3 of this Part; and
(3) collected the following information for the purposes of the authority application:
a. the patient’s hepatitis C virus genotype; and
b. whether the patient is:
i. cirrhotic; or
ii. Non‑cirrhotic
(4) In this paragraph, evidence of chronic hepatitis C infection is documentation of:
a. repeat test results showing antibody to hepatitis C virus (anti‑HCV) positive; and
b. test result showing hepatitis C virus ribonucleic acid (RNA) positive
3 Treatment regimen
For the purpose of subparagraph 2(2) of this Part, the treating medical practitioner has chosen a regimen in accordance with this paragraph if the patient:
(1) is a kind of patient mentioned for an Item in column 2 of the following table; and
(2) is to receive one of the regimens mentioned in column 3 of the same Item of the following table
| Item | Kind of patient | Regimen |
| 1 | Patient: (a) with Genotype 1; and (b) who is treatment naïve; and (c) who is non‑cirrhotic | Either: (a) LEDIPASVIR with SOFOSBUVIR for 8 weeks; or (b) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or (c) DACLATASVIR and SOFOSBUVIR for 12 weeks; or (d) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR for 12 weeks; or (f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks; or (g) GRAZOPREVIR with ELBASVIR for 12 weeks; or (h) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 2 | Patient: (a) with Genotype 1; and (b) who is treatment experienced; and (c) who is non‑cirrhotic | Either: (a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or (b) DACLATASVIR and SOFOSBUVIR for 12 weeks; or (c) DACLATASVIR and SOFOSBUVIR for 24 weeks; or (d) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR for 12 weeks; or (f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks; or (g) GRAZOPREVIR with ELBASVIR for 12 weeks; or (h) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks; or (i) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 3 | Patient: (a) with Genotype 2; and (b) who is treatment naïve; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 4 | Patient: (a) with Genotype 2; and (b) who is treatment experienced; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 5 | Patient: (a) with Genotype 3; and (b) who is treatment naïve; and (c) who is non‑cirrhotic | Either: (a) DACLATASVIR and SOFOSBUVIR for 12 weeks; or (b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (c) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (d) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 6 | Patient: (a) with Genotype 3; and (b) who is treatment experienced; and (c) who is non‑cirrhotic | Either: (a) DACLATASVIR and SOFOSBUVIR for 12 weeks; or (b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (c) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (d) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 7 | Patient: (a) with Genotype 4; and (b) who is treatment naïve; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or (c) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 8 | Patient: (a) with Genotype 4; and (b) who is treatment experienced; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or (c) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks; or (d) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 9 | Patient: (a) with: (i) Genotype 5; or (ii) Genotype 6; and (b) who is treatment naïve; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 10 | Patient: (a) with: (i) Genotype 5; or (ii) Genotype 6; and (b) who is treatment experienced; and (c) who is non‑cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 11 | Patient: (a) with Genotype 1; and (b) who is treatment naïve; and (c) who is cirrhotic | Either: (a) LEDIPASVIR with SOFOSBUVIR for 12 weeks; or (b) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (c) DACLATASVIR and SOFOSBUVIR for 24 weeks; or (d) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks; or (f) GRAZOPREVIR with ELBASVIR for 12 weeks; or (g) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 12 | Patient: (a) with Genotype 1; and (b) who is treatment experienced; and (c) who is cirrhotic | Either: (a) LEDIPASVIR with SOFOSBUVIR for 24 weeks; or (b) DACLATASVIR and SOFOSBUVIR for 24 weeks; or (c) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (d) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (e) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 12 weeks; or (f) PARITAPREVIR with RITONAVIR with OMBITASVIR and DASABUVIR and RIBAVIRIN for 24 weeks; or (g) GRAZOPREVIR with ELBASVIR for 12 weeks; or (h) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks; or (i) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 13 | Patient: (a) with Genotype 2; and (b) who is treatment naïve; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 14 | Patient: (a) with Genotype 2; and (b) who is treatment experienced; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 15 | Patient: (a) with Genotype 3; and (b) who is treatment naïve; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (b) DACLATASVIR and SOFOSBUVIR for 24 weeks; or (c) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (d) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (e) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (f) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 16 | Patient: (a) with Genotype 3; and (b) who is treatment experienced; and (c) who is cirrhotic | Either: (a) DACLATASVIR and SOFOSBUVIR for 24 weeks; or (b) SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (c) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (d) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 12 weeks; or (e) DACLATASVIR and SOFOSBUVIR and RIBAVIRIN for 24 weeks; or (f) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 17 | Patient: (a) with Genotype 4; and (b) who is treatment naïve; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or (c) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 18 | Patient: (a) with Genotype 4; and (b) who is treatment experienced; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) GRAZOPREVIR with ELBASVIR for 12 weeks; or (c) GRAZOPREVIR with ELBASVIR and RIBAVIRIN for 16 weeks; or (d) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 19 | Patient: (a) with: (i) Genotype 5; or (ii) Genotype 6; and (b) who is treatment naïve; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
| 20 | Patient: (a) with: (i) Genotype 5; or (ii) Genotype 6; and (b) who is treatment experienced; and (c) who is cirrhotic | Either: (a) SOFOSBUVIR and PEGINTERFERON ALFA‑2A and RIBAVIRIN for 12 weeks; or (b) SOFOSBUVIR with VELPATASVIR for 12 weeks. |
Schedule 4—Patient contributions
| Listed Drug | Form (strength, type, size, etc.) | Manner of Administration | Brand | Pack Quantity | Approved Ex‑manufacturer Price or Proportional Ex‑manufacturer Price $ | Claimed price $ |
| Lamivudine | Tablet 100 mg | Oral | Zeffix | 28 | $34.70 | $35.30 |
| Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | Valtrex | 100 | $44.20 | $44.64 |
Endnotes
Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.
If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.
If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.
Endnote 2—Abbreviation key
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = Legislation Act 2003 | Sch = Schedule(s) |
| LIA = Legislative Instruments Act 2003 | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |
Endnote 3—Legislation history
| Name | Registration | Commencement | Application, saving and transitional provisions |
| PB 116 of 2010 | 29 Nov 2010 (F2010L03140) | 1 Dec 2010 (s 2) | |
| PB 122 of 2010 | 17 Dec 2010 (F2010L03308) | 1 Jan 2010 (s 2) | — |
| PB 2 of 2011 | 31 Jan 2011 (F2011L00168) | 1 Feb 2011 (s 2) | — |
| PB 16 of 2011 | 28 Feb 2011 (F2011L00316) | 1 Mar 2011 (s 2) | — |
| PB 28 of 2011 | 31 Mar 2011 (F2011L00546) | 1 Apr 2011 (s 2) | — |
| PB 34 of 2011 | 27 Apr 2011 (F2011L00643) | 1 May 2011 (s 2) | — |
| PB 38 of 2011 | 31 May 2011 (F2011L00893) | 1 June 2011 (s 2) | — |
| PB 46 of 2011 | 24 June 2011 (F2011L01221) | 1 July 2011 (s 2) | — |
| PB 53 of 2011 | 27 July 2011 (F2011L01543) | 1 Aug 2011 (s 2) | — |
| PB 62 of 2011 | 31 Aug 2011 (F2011L01777) | 1 Sept 2011 (s 2) | — |
| PB 69 of 2011 | 28 Sept 2011 (F2011L01978) | 1 Oct 2011 (s 2) | — |
| PB 76 of 2011 | 26 Oct 2011 (F2011L02130) | 1 Nov 2011 (s 2) | — |
| PB 86 of 2011 | 30 Nov 2011 (F2011L02501) | 1 Dec 2011 (s 2) | — |
| PB 99 of 2011 | 15 Dec 2011 (F2011L02694) | 1 Jan 2011 (s 2) | — |
| PB 5 of 2012 | 23 Feb 2012 (F2012L00380) | 1 Mar 2012 (s 2) | — |
| PB 20 of 2012 | 29 Mar 2012 (F2012L00716) | 1 Apr 2012 (s 2) | — |
| PB 31 of 2012 | 30 Apr 2012 (F2012L00952) | 1 May 2012 (s 2) | — |
| PB 35 of 2012 | 30 May 2012 (F2012L01122) | 1 June 2012 (s 2) | — |
| PB 39 of 2012 | 29 June 2012 (F2012L01458) | 1 July 2012 (s 2) | — |
| PB 47 of 2012 | 26 July 2012 (F2012L01615) | 1 Aug 2012 (s 2) | — |
| PB 64 of 2012 | 29 Aug 2012 (F2012L01783) | 1 Sept 2012 (s 2) | — |
| PB 76 of 2012 | 28 Sept 2012 (F2012L01971) | 1 Oct 2012 (s 2) | — |
| PB 96 of 2012 | 30 Oct 2012 (F2012L02107) | 30 Oct 2012 (s 2) | — |
| PB 106 of 2012 | 29 Nov 2012 (F2012L02286) | 1 Dec 2012 (s 2) | — |
| PB 110 of 2012 | 17 Dec 2012 (F2012L02508) | 1 Jan 2013 (s 2) | — |
| PB 10 of 2013 | 21 Feb 2013 (F2013L00245) | 1 Mar 2013 (s 2) | — |
| PB 16 of 2013 | 27 Mar 2013 (F2013L00562) | 1 Apr 2013 (s 2) | — |
| PB 30 of 2013 | 30 May 2013 (F2013L00874) | 1 June 2013 (s 2) | — |
| PB 42 of 2013 | 31 July 2013 (F2013L01483) | 1 Aug 2013 (s 2) | — |
| PB 56 of 2013 | 27 Aug 2013 (F2013L01630) | 1 Sept 2013 (s 2) | — |
| PB 63 of 2013 | 24 Sept 2013 (F2013L01736) | 1 Oct 2013 (s 2) | — |
| PB 70 of 2013 | 18 Oct 2013 (F2013L01812) | 1 Nov 2013 (s 2) | — |
| PB 78 of 2013 | 29 Nov 2013 (F2013L02011) | 1 Dec 2013 (s 2) | — |
| PB 92 of 2013 | 24 Dec 2013 (F2013L02191) | 1 Jan 2014 (s 2) | — |
| PB 4 of 2014 | 28 Jan 2014 (F2014L00098) | 1 Feb 2014 (s 2) | — |
| PB 11 of 2014 | 25 Feb 2014 (F2014L00183) | 1 Mar 2014 (s 2) | — |
| PB 20 of 2014 | 31 Mar 2014 (F2014L00372 | 1 Apr 2014 (s 2) | — |
| PB 30 of 2014 | 29 Apr 2014 (F2014L00449) | 1 May 2014 (s 2) | — |
| PB 40 of 2014 | 21 May 2014 (F2014L00577) | 1 June 2014 (s 2) | — |
| PB 48 of 2014 | 20 June 2014 (F2014L00766) | 1 July 2014 (s 2) | — |
| PB 55 of 2014 | 31 July 2014 (F2014L01065) | 1 Aug 2014 (s 2) | — |
| PB 63 of 2014 | 25 Aug 2014 (F2014L01126) | 1 Sept 2014 (s 2) | — |
| PB 93 of 2014 | 1 Dec 2014 (F2014L01610) | 1 Dec 2014 (s 2) | — |
| PB 102 of 2014 | 24 Dec 2014 (F2014L01834) | 1 Jan 2015 (s 2) | — |
| PB 3 of 2015 | 30 Jan 2015 (F2015L00087) | 1 Feb 2015 (s 2) | — |
| PB 30 of 2015 | 1 Apr 2015 (F2015L00457) | 1 Apr 2015 (s 2) | — |
| PB 43 of 2015 | 29 Apr 2015 (F2015L00607) | 1 May 2015 (s 2) | — |
| PB 50 of 2015 | 1 June 2015 (F2015L00770) | 1 June 2015 (s 2) | — |
| PB 58 of 2015 | 1 July 2015 (F2015L01073) | 1 July 2015 (s 2) | — |
| PB 72 of 2015 | 31 July 2015 (F2015L01214) | 1 Aug 2015 (s 2) | — |
| PB 83 of 2015 | 1 Sept 2015 (F2015L01370) | 1 Sept 2015 (s 2) | — |
| PB 94 of 2015 | 1 Oct 2015 (F2015L01619) | 1 Oct 2015 (s 2) | — |
| PB 104 of 2015 | 30 Oct 2015 (F2015L01723) | 1 Nov 2015 (s 2) | — |
| PB 111 of 2015 | 1 Dec 2015 (F2015L01908) | 1 Dec 2015 (s 2) | — |
| PB 121 of 2015 | 18 Dec 2015 (F2015L02085) | 18 Dec 2015 (s 2) | — |
| PB 129 of 2015 | 24 Dec 2015 (F2015L02138) | 1 Jan 2016 (s 2) | — |
| PB 5 of 2016 | 1 Feb 2016 (F2016L00076) | 1 Feb 2016 (s 2) | — |
| PB 13 of 2016 | 1 Mar 2016 (F2016L00216) | 1 Mar 2016 (s 2) | — |
| PB 22 of 2016 | 1 Apr 2016 (F2016L00473) | 1 Apr 2016 (s 2) | — |
| PB 33 of 2016 | 29 Apr 2016 (F2016L00607) | 1 May 2016 (s 2) | — |
| PB 45 of 2016 | 31 May 2016 (F2016L00924) | 1 June 2016 (s 2) | — |
| PB 55 of 2016 | 28 June 2016 (F2016L01091) | 1 July 2016 (s 2) | — |
| PB 67 of 2016 | 28 July 2016 (F2016L01240) | 1 Aug 2016 (s 2) | — |
| PB 76 of 2016 | 30 Aug 2016 (F2016L01365) | 1 Sept 2016 (s 2) | — |
| PB 84 of 2016 | 30 Sept 2016 (F2016L01559) | 1 Oct 2016 (s 2) | — |
| PB 93 of 2016 | 31 Oct 2016 (F2016L01664) | 1 Nov 2016 (s 2) | — |
| PB 100 of 2016 | 30 Nov 2016 (F2016L01842) | 1 Dec 2016 (s 2) | — |
| PB 113 of 2016 | 22 Dec 2016 (F2016L02027) | 1 Jan 2017 (s 2) | — |
| PB 5 of 2017 | 25 Jan 2017 (F2017L00066) | 1 Feb 2017 (s 2) | — |
| PB 20 of 2017 | 31 Mar 2017 (F2017L00378) | 1 Apr 2017 (s 2) | — |
| PB 30 of 2017 | 28 Apr 2017 (F2017L00489) | 1 May 2017 (s 2) | — |
| PB 39 of 2017 | 31 May 2017 (F2017L00634) | 1 June 2017 (s 2) | — |
| PB 47 of 2017 | 30 June 2017 (F2017L00856) | 1 July 2017 (s 2) | — |
| PB 57 of 2017 | 27 July 2017 (F2017L00959) | 1 Aug 2017 (s 2) | — |
| PB 66 of 2017 | 31 Aug 2017 (F2017L01117) | 1 Sept 2017 (s 2) | — |
| PB 75 of 2017 | 26 Sept 2017 (F2017L01271) | 1 Oct 2017 (s 2) | — |
| PB 88 of 2017 | 30 Oct 2017 (F2017L01399) | 1 Nov 2017 (s 2) | — |
Endnote 4—Amendment history
| Provision affected | How affected |
| Part 1 | |
| Division 1 | |
| s 1............................................. | am PB 58 of 2015 |
| s 2............................................. | rep LA s 48D |
| s 3............................................. | rep LA s 48C |
| s 4............................................. | am PB 122 of 2010; PB 2, 16, 28, 46, 62 and 99 of 2011; PB 20, 31, 35, 39 and 76 of 2012; PB 20, 63 and 93 of 2014; PB 3, 30 and 58 of 2015; PB 72 of 2015 (Sch 1 item 1 md); PB 33, 67, 76, 84 and 113 of 2016; PB 30 of 2017; PB 66 of 2017; PB 75 of 2017 |
| Division 2 | |
| s 9A.......................................... | ad PB 93 of 2014 |
| Division 3 | |
| Division 3 heading.................... | rs PB 30 of 2015 |
| Division 3................................. | am PB 30 of 2015 |
| s 10........................................... | am PB 62 of 2011; PB 30 of 2015; PB 33 of 2016 |
| s 11........................................... | am PB 62 of 2011 |
| rep PB 30 of 2015 | |
| s 12........................................... | am PB 62 of 2011 |
| rep PB 30 of 2015 | |
| s 13........................................... | am PB 62 of 2011 |
| rep PB 30 of 2015 | |
| Part 2 | |
| Division 1 | |
| s 17A........................................ | ad PB 93 of 2014 |
| s 18........................................... | am PB 30 and 58 of 2015 |
| rs PB 33 of 2016 | |
| s 18A........................................ | ad PB 58 of 2015 |
| Division 2 | |
| s 19........................................... | am PB 30 an 58 of 2015 |
| Division 3 | |
| s 21........................................... | am PB 30 of 2015 |
| s 22........................................... | rep PB 30 of 2015 |
| s 22A........................................ | ad PB 93 of 2014 |
| Division 4 | |
| s 23........................................... | am PB 30 of 2015 |
| s 23A........................................ | ad PB 93 of 2014 |
| s 24........................................... | am PB 2, 28, 46 and 99 of 2011; PB 5, 20 and 31 of 2012 |
| rs PB 63 of 2013 | |
| am PB 113 of 2016; PB 5 of 2017; PB 66 of 2017 | |
| ed C74 | |
| am PB 75 of 2017; PB 88 of 2017 | |
| s 25........................................... | am PB 2, 28, 46 and 99 of 2011; PB 20 and 31 of 2012 |
| rs PB 63 of 2013 | |
| am PB 113 of 2016; PB 5 of 2017; PB 66 of 2017 | |
| ed C74 | |
| am PB 75 of 2017; PB 88 of 2017 | |
| s 26........................................... | rs PB 30 of 2015 |
| Part 3........................................ | rep PB 30 of 2015 |
| s 27........................................... | rep PB 30 of 2015 |
| Part 4 | |
| Division 1............................................... | rep PB 30 of 2015 |
| s 28........................................... | am PB 62 of 2011; PB 76 of 2012 |
| rep PB 30 of 2015 | |
| s 29........................................... | rep PB 30 of 2015 |
| Division 2 | |
| Subdivision 1 | |
| s 30........................................... | am PB 30 of 2015 |
| Subdivision 2............................ | rep PB 30 of 2015 |
| s 32........................................... | rep PB 30 of 2015 |
| s 33........................................... | am PB 39 of 2012 |
| rep PB 30 of 2015 | |
| s 34........................................... | rep PB 30 of 2015 |
| Division 3 | |
| Division 3 heading.................... | am PB 58 of 2015 |
| s 36........................................... | am PB 58 of 2015 |
| Part 5 | |
| Division 1 | |
| s 37........................................... | am PB 76 and 96 of 2012 |
| s 38........................................... | rs PB 76 of 2012 |
| Division 2 | |
| Division 2 heading.................... | am PB 58 of 2015 |
| s 39........................................... | am PB 122 of 2010; PB 76 of 2012; PB 58 of 2015 |
| s 40........................................... | am PB 76 and 96 of 2012 |
| s 41........................................... | rs PB 76 of 2012 |
| Division 3 | |
| s 43........................................... | am PB 122 of 2010 |
| rep PB 76 of 2012 | |
| Part 6 | |
| s 45........................................... | am PB 122 of 2010; PB 5 and 106 of 2012 |
| rep PB 30 of 2015 | |
| s 46........................................... | am PB 106 of 2012; PB 30 of 2015 |
| s 47........................................... | am PB 106 of 2012; PB 30 and 58 of 2015 |
| s 48........................................... | am PB 76 of 2012 |
| rs PB 106 of 2012 | |
| am PB 30 of 2015 | |
| Part 7 | |
| s 49........................................... | am PB 62 of 2011 |
| rs PB 58 of 2015 | |
| s 50........................................... | am PB 30 and 58 of 2015 |
| s 51........................................... | am PB 20 of 2012; PB 30 and 58 of 2015 |
| Part 8 | |
| s 52........................................... | am PB 62 of 2011 |
| Part 9 | |
| s 54........................................... | rep PB 30 of 2015 |
| ad PB 30 of 2015 | |
| s 55........................................... | rep PB 30 of 2015 |
| ad PB 30 of 2015 | |
| s 56........................................... | ad PB 58 of 2015 |
| Schedule 1 | |
| Schedule 1................................ | am PB 122 of 2010; PB 2, 28, 34, 38, 46, 53, 62, 69, 76, 86 and 99 of 2011; PB 5, 20, 31, 35, 39, 47, 64, 76, 106 and 110 of 2012; PB 10, 16, 30, 42, 56, 63, 70, 78 and 92 of 2013; PB 4, 11, 20, 30, 40, 48, 55 and 63 of 2014; PB 93 of 2014 (Sch 1 items 13, 14 md); PB 102 of 2014; PB 3, 30, 43, 50, 58, 72, 83, 94, 104, 111, 121 and 129 of 2015; PB 5 and 13 of 2016; PB 22 of 2016 (Sch 1 items 1‑3, 6 md); PB 33, 45, 55, 67 and 76 of 2016; PB 84 of 2016 (Sch 1 item 8 md); PB 93, 100 and 113 of 2016; PB 5 of 2017; PB 20 of 2017; PB 30 of 2017; PB 39 of 2017; PB 47 of 2017; PB 57 of 2017; PB 66 of 2017; PB 75 of 2017; PB 88 of 2017 |
| Schedule 2 | |
| Schedule 2................................ | am PB 122 of 2010; PB 34, 46, 53 and 69 of 2011; PB 5, 20, 31, 47, 76, 106 and 110 of 2012; PB 16 of 2013 |
| rs PB 63 of 2013 | |
| am PB 11, 93 and 102 of 2014; PB 30, 72, 94 and 104 of 2015; PB 5, 22, 67, 93 and 113 of 2016; PB 20 of 2017 | |
| Schedule 3 | |
| Schedule 3................................ | am PB 122 of 2010; PB 16, 28, 34, 38, 46, 62, 76, 86 and 99 of 2011; PB 5, 20, 31, 35, 39, 47 and 106 of 2012; PB 16, 56, 63, 70, 78 and 92 of 2013; PB 4, 20, 30, 40, 48 and 63 of 2014; PB 93 of 2014 (Sch 1 item 24 md); PB 3, 30, 43, 50, 58, 72, 83, 94, 104, 111, 121 and 129 of 2015; PB 5, 13, 22, 33, 45, 55, 67, 76, 84, 93, 100 and 113 of 2016; PB 5 of 2017; PB 30 of 2017; PB 39 of 2017; PB 47 of 2017; PB 57 of 2017; PB 66 of 2017; PB 75 of 2017; PB 88 of 2017 |
| Part 1 | |
| c 1............................................. | ad PB 13 of 2016 |
| rs PB 113 of 2016; PB 39 of 2017 | |
| c 2............................................. | ad PB 13 of 2016 |
| rs PB 113 of 2016 | |
| c 3............................................. | ad PB 13 of 2016 |
| rs PB 113 of 2016 | |
| am PB 5 of 2017; PB 66 of 2017; PB 75 of 2017 | |
| Schedule 4 | |
| Schedule 4................................ | am PB 28 of 2011 |
| rs PB 38 of 2011 | |
| am PB 47 of 2012 | |
| rs PB 76 of 2012; PB 16 of 2013; PB 84 and 100 of 2016; PB 20 of 2017; PB 75 of 2017 |
0
0
0